1. Ali visoko maligni B-celični limfomi, dvojni ekspresorji, res potrebujejo intenzivnejšo kemoterapijoLučka Boltežar, Samo Rožman, Gorana Gašljević, Biljana Grčar-Kuzmanov, Barbara Jezeršek Novaković, 2023, published scientific conference contribution Abstract: Velikocelični B limfomi z BCL2 in BCL6 preureditvijo so imenovani "double-hit" oziroma "triplehit" limfomi, z imunohistokemično ekspresijo pa dvojni ekspresorji (DE) in vsi imajo slabšo prognozo od klasičnih velikoceličnih limfomov B. Opravljena je bila študija vseh bolnikov z visoko malignimi B limfomi in difuznim velikoceličnim limfomom B, zdravljenih na Onkološkem inštitutu Ljubljana med leti 2017 in 2021. Večina izmed 154 vključenih bolnikov je bila zdravljenih z R-CHOP terapijo (rituksimab, ciklofosfamid, doksorubicin, vinkristin in prednizon), mediani čas spremljanja bolnikov je bil 22 mesecev. 110 bolnikov (71,4 %) ni imelo ponovitve bolezni v opazovanem obdobju. V primerjavi štirih uporabljenih terapevtskih protokolov v skupini DE nismo našli razlik v preživetju (p < 0,712). Preživetje bolnikov z "double-hit" in "triple-hit" limfomi je bilo, pričakovano, slabo. Naši podatki kažejo, da je velik del bolnikov z DE, zdravljen z R-CHOP in standardno CŽS profilakso, tudi uspešno ozdravljen. Za potrditev naših izsledkov so potrebne večje randomizirane raziskave.
Keywords: limfomi, kemoterapija, onkološko zdravljenje
Published in DiRROS: 16.06.2023; Views: 209; Downloads: 82
 Full text (1,93 MB)
This document has many files! More... |
2. Izraženost ER in PR pri invazivnem karcinomu dojke : rezultati določanja na 15 029 zaporednih vzorcih z Onkološkega Inštituta v obdobju 2006 do 2021Primož Drev, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Barbara Gazić, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija
Published in DiRROS: 14.02.2023; Views: 258; Downloads: 91
Full text (79,90 KB) |
3. Izraženost hormonskih receptorjev pri invazivnem karcinomu dojke : rezultati določanja na 15029 zaporednih vzorcih z Onkološkega Inštituta v obdobju od 2006 do 2021Barbara Gazić, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Primož Drev, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija
Published in DiRROS: 14.02.2023; Views: 260; Downloads: 58
Full text (87,23 KB) |
4. HER2 pri invazivnem karcinomu dojke – rezultati določanja na 15 184 zaporednih vzorcih z Onkološkega Inštituta v obdobju 2006 do 2021Primož Drev, Olga Blatnik, Jerca Blazina, Juan Antonio Contreras, Gorana Gašljević, Biljana Grčar-Kuzmanov, Andreja Klevišar Ivančič, Snežana Pavlović Djokić, Barbara Gazić, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, patologija
Published in DiRROS: 14.02.2023; Views: 228; Downloads: 62
Full text (107,23 KB) |
5. Pomen PIK3CA aktivirajočih mutacij za izid bolezni pri bolnicah z invazivnim lobularnim karcinomom dojke, zdravljenih z dopolnilno endokrino terapijoDomen Ribnikar, Valentina Jerič Horvat, Ivica Ratoša, Zachary Veitch, Biljana Grčar-Kuzmanov, Srdjan Novaković, Erik Langerholc, Maja Pohar Perme, Eitan Amir, Boštjan Šeruga, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 27.01.2023; Views: 242; Downloads: 74
Full text (46,13 KB) |
6. Priporočila za obravnavo bolnikov z malignimi limfomiBarbara Jezeršek Novaković, Lučka Boltežar, Andreja Eberl, Gorana Gašljević, Biljana Grčar-Kuzmanov, Monika Jagodic, Tanja Južnič Šetina, Veronika Kloboves-Prevodnik, Gregor Kos, Aleš Christian Mihelač, Milica Miljković, Urška Rugelj, Marija Skoblar Vidmar, Uroš Smrdel, Danijela Štrbac, Miha Toplak, Lorna Zadravec-Zaletel, 2023, professional monograph Keywords: maligni limfomi, smernice, novotvorbe
Published in DiRROS: 24.01.2023; Views: 457; Downloads: 199
Full text (971,73 KB)
This document has many files! More... |
7. BAP1-defficient breast cancer in a patient with BAP1 cancer syndromeAna Blatnik, Domen Ribnikar, Vita Šetrajčič Dragoš, Srdjan Novaković, Vida Stegel, Biljana Grčar-Kuzmanov, Nina Boc, Barbara Perić, Petra Škerl, Gašper Klančar, Mateja Krajc, 2022, original scientific article Abstract: BAP1 cancer syndrome is a rare and highly penetrant hereditary cancer predisposition. Uveal melanoma, mesothelioma, renal cell carcinoma (RCC) and cutaneous melanoma are considered BAP1 cancer syndrome core cancers, whereas association with breast cancer has previously been suggested but not confirmed so far. In view of BAP1 immunomodulatory functions, BAP1 alterations could prove useful as possible biomarkers of response to immunotherapy in patients with BAP1-associated cancers. We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry. She carried a germline BAP1 likely pathogenic variant (c.898_899delAG p.(Arg300Glyfs*6)). In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel. This case strengthens the evidence for including breast cancer in the BAP1 cancer syndrome tumor spectrum with implications for future cancer prevention programs. It also indicates immune checkpoint inhibitors might prove to be an effective treatment for BAP1-deficient breast cancer.
Keywords: BAP1, breast cancer, hereditary cancer syndromes, immunotherapy
Published in DiRROS: 19.09.2022; Views: 327; Downloads: 130
Full text (1,12 MB) |
8. Priporočila za obravnavo bolnikov z malignimi limfomiBarbara Jezeršek Novaković, Gorana Gašljević, Biljana Grčar-Kuzmanov, Monika Jagodic, Tanja Južnič Šetina, Veronika Kloboves-Prevodnik, Gregor Kos, Milica Miljković, Jana Pahole Goličnik, Samo Rožman, Urška Rugelj, Marija Skoblar Vidmar, Uroš Smrdel, Danijela Štrbac, Miha Toplak, Lorna Zadravec-Zaletel, Mateja Dolenc-Voljč, 2021, professional monograph Keywords: maligni limfomi, smernice, novotvorbe
Published in DiRROS: 17.03.2022; Views: 579; Downloads: 304
Full text (1,61 MB)
This document has many files! More... |
9. Priporočila za obravnavo bolnikov z malignimi limfomiBarbara Jezeršek Novaković, Lučka Boltežar, Gorana Gašljević, Biljana Grčar-Kuzmanov, Monika Jagodic, Tanja Južnič Šetina, Veronika Kloboves-Prevodnik, Gregor Kos, Milica Miljković, Jana Pahole Goličnik, Samo Rožman, Urška Rugelj, Marija Skoblar Vidmar, Uroš Smrdel, Danijela Štrbac, Miha Toplak, Lorna Zadravec-Zaletel, Mateja Dolenc-Voljč, 2022, professional monograph Keywords: maligni limfomi, smernice, novotvorbe
Published in DiRROS: 14.03.2022; Views: 616; Downloads: 341
Full text (3,61 MB)
This document has many files! More... |
10. Programske smernice Državnega programa ZORAUrška Ivanuš, Edita Arh, Sonja Bebar, Branko Cvjetičanin, Dušan Deisinger, Mojca Florjančič, Aljoša Frelih, Urška Gašper, Biljana Grčar-Kuzmanov, Nina Jančar, Tine Jerman, Kaja Kališnik, Silvestra Kašnik-Čas, Veronika Kloboves-Prevodnik, Borut Kobal, Amela Duratović Konjević, Jerneja Kos, Gabrijela Kupljen, Mateja Lasič Pecev, Mateja Marčec, Leon Meglič, Sebastjan Merlo, Marko Mlinarič, Nataša Nolde, Irena Oblak, Maja Pakiž, Boštjan Pirš, Ana Pogačnik, Maja Primic-Žakelj, Alenka Repše-Fokter, Luka Roškar, Uršula Salobir Gajšek, Špela Sitar, Špela Smrkolj, Vivijana Snoj, Margareta Strojan Fležar, Tadeja Štrumbelj, Iztok Takač, Renata Toff-Jovan, Tomaž Tušek, Andreja Uštar, 2022, professional monograph Keywords: predrakave spremembe, zgodnja diagnostika, presejanje, presejalni programi, nacionalni programi, postopki, elektronske knjige
Published in DiRROS: 10.03.2022; Views: 632; Downloads: 295
Full text (1,68 MB)
This document has many files! More... |
